We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
+$23.6M
Cap. Flow
+$98.4M
Cap. Flow %
3.98%
Top 10 Hldgs %
53.52%
Holding
129
New
25
Increased
23
Reduced
34
Closed
26

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$125M
2
Z icon
Zillow
Z
+$35.8M
3
UBER icon
Uber
UBER
+$21.2M
4
CYCN icon
Cyclerion Therapeutics
CYCN
+$19.3M
5
HOOK
HOOKIPA Pharma
HOOK
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$48.8M
2
IFRX icon
InflaRx
IFRX
+$31.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$11M
4
WVE icon
Wave Life Sciences
WVE
+$9.71M
5
VICI icon
VICI Properties
VICI
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 63.4%
2 Consumer Discretionary 15.74%
3 Technology 4.81%
4 Communication Services 1.88%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
76
BridgeBio Pharma
BBIO
$16.6B
$5.39M 0.22%
+200,000
New +$5.45M
ALLO icon
77
Allogene Therapeutics
ALLO
$580M
$5.37M 0.22%
200,000
-200,000
-50% -$5.57M
MRUS
78
DELISTED
Merus
MRUS
$5.13M 0.21%
350,000
+50,000
+17% +$711K
AGIO icon
79
CALL
Agios Pharmaceuticals
AGIO
$2.1B
$4.99M 0.2%
100,000
-100,000
-50% -$5.34M
ORTX
80
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.9M 0.2%
+35,000
New +$6.15M
CRSP icon
81
CRISPR Therapeutics
CRSP
$4.65B
$4.71M 0.19%
100,000
-45,000
-31% -$1.8M
NIO icon
82
CALL
NIO
NIO
$12.2B
$4.46M 0.18%
1,750,000
– –
SGMO
83
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.36M 0.18%
405,000
+5,000
+1% +$53.2K
FTDR icon
84
Frontdoor
FTDR
$5.18B
$4.36M 0.18%
+100,000
New +$3.84M
ALEC icon
85
Alector
ALEC
$167M
$4.28M 0.17%
225,000
-25,000
-10% -$507K
RNAC icon
86
Cartesian Therapeutics
RNAC
$224M
$3.76M 0.15%
70,000
– –
ACET icon
87
Adicet Bio
ACET
$76.7M
$3.67M 0.15%
3,214
-357
-10% -$324K
MDGL icon
88
Madrigal Pharmaceuticals
MDGL
$12.5B
$3.67M 0.15%
35,000
– –
AXLA
89
DELISTED
Axcella Health Inc. Common Stock
AXLA
$3.63M 0.15%
+15,590
New +$4.94M
NKTR icon
90
CALL
Nektar Therapeutics
NKTR
$2.34B
$3.56M 0.14%
6,667
– –
TWST icon
91
Twist Bioscience
TWST
$5.38B
$2.9M 0.12%
100,000
-50,000
-33% -$1.32M
YI
92
111 Inc
YI
$34.7M
$2.5M 0.1%
45,000
– –
RCUS icon
93
Arcus Biosciences
RCUS
$3.37B
$2.15M 0.09%
270,000
-30,000
-10% -$300K
AKBA icon
94
Akebia Therapeutics
AKBA
$335M
$2.06M 0.08%
425,000
-50,000
-11% -$284K
ARAV
95
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.84M 0.07%
307,466
+51,197
+20% +$319K
KDNY
96
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.54M 0.06%
200,000
– –
NGM
97
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.46M 0.06%
+100,000
New +$1.46M
TECX
98
Tectonic Therapeutic
TECX
$553M
$1.46M 0.06%
7,500
-833
-10% -$180K
IRWD icon
99
Ironwood Pharmaceuticals
IRWD
$614M
$1.21M 0.05%
110,532
-21,443
-16% -$240K
SYRE icon
100
Spyre Therapeutics
SYRE
$8.47B
$1.16M 0.05%
+6,758
New +$1.17M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2019 Portfolio in Review

As of Q2 2019, Artal Group held 129 positions worth $2.47B, up 0.96% from $2.45B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Artal Group deployed $98.4M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Avantor: 7,000,000 shares worth $134M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 64% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $8.59M trimmed.

  • Artal Group's largest Q2 2019 buy was Avantor: 7,000,000 shares worth $134M.
  • Artal Group added most to Zillow in Q2 2019, an estimated $35.8M increase.
  • Artal Group's biggest Q2 2019 reduction was Moderna, cutting an estimated $8.59M.
  • Artal Group fully exited Array Biopharma Inc in Q2 2019, selling an estimated $48.8M.
  • Artal Group's ten largest holdings make up 54% of its $2.47B portfolio in Q2 2019.
  • Artal Group opened 25 new positions and closed 26 in Q2 2019.
  • Artal Group's portfolio value rose 0.96% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.